New NZ company receives $12.5 million for PI3K research « Kinase News

Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

New NZ company receives $12.5 million for PI3K research

Posted on June 18, 2008 by crimsoncanary

New Zealand company Pathway Therapeutics, a spin off from University of Auckland, has received $12.5 million in funding for its work on PI3K inhibitors

Filed under: kinase | Tagged: Funding, kinase, Pathway Therapeutics, PI3K, Preclinical, Research

« Cytopia to present update on FMS program Rhabdomyolysis – possible adverse effect of Imatinib »